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We followed 353 women referred with abnormal cervical cytology in a non-intervention cohort study. In 91 pregnant women
we compared high-risk human papilloma virus rates in the subsequent trimesters and postpartum in comparison to 262 non-
pregnant women. High-risk human papilloma virus clearance was compared with 179 high-risk human papilloma virus positive
non-pregnant women. Our main questions were: (1) do high-risk human papilloma virus rates change during pregnancy?; and
(2) is there any difference between high-risk human papilloma virus clearance in pregnant and non-pregnant women? Women
were monitored 3–4 monthly by cytology, colposcopy, and high-risk human papilloma virus testing. The median follow-up
time was 33 months (range 3–74). Non-pregnant women showed prevalence rates of high-risk human papilloma virus of 64,
57, 53, and 50%, respectively, in four subsequent 3-months periods since the start of the study. These high-risk human
papilloma virus rates were higher than in the three trimesters of pregnancy, and during the ﬁrst 3 months postpartum, i.e. 50,
44, 45, and 31%, respectively. Postpartum only, this difference was statistically signiﬁcant (P=0.004). Paired comparisons of
high-risk human papilloma virus prevalence rates of the different trimesters with the postpartum rate showed (McNemar test)
decreased rates: ﬁrst trimester: 18% (P=0.02), second trimester: 13% (P=0.02) and third trimester: 23% (P50.005). Such a
phenomenon was not found in non-pregnant women. Pregnant women showed a trend for increased high-risk human
papilloma virus clearance during the third trimester and postpartum compared to non-pregnant women (hazard ratios 3.3
(0.8–13.7) and 4.6 (1.6–12.8), respectively). These results suggest a lowered immune-response against human papilloma virus
during the ﬁrst two trimesters of pregnancy with a catch-up postpartum.
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Several epidemiological and biological studies have established the
important role of infection with high-risk types of human papillo-
ma virus (HPV) for development of cervical cancer and its
precursor lesions. In women with or without abnormal cervical
smears a positive high-risk HPV test result indicates an increased
risk for development of high grade cervical lesions (Ho et al,
1995; Remmink et al, 1995; Rozendaal et al, 1996, 2000; Nobben-
huis et al, 1999). Moreover, in nearly all cervical cancers high-risk
HPV types have been detected (Walboomers et al, 1999).
The increased prevalence of high grade cervical lesions and
cervical cancer in immunocompromised patients, such as AIDS
patients and transplant recipients, indicates that persistence of
high-risk HPV and consequently HPV-mediated carcinogenesis is
related to compromised immunosurveillance (IARC, 1995; Petry
et al, 1996; Sun et al, 1997). Pregnancy is believed to alter
immune-response in women (Schneider et al, 1987; Sethi et al,
1998). Some authors concluded pregnancy has no effect on CIN
(Jain et al, 1997). Others reported high regression rates of cervical
dysplasia in the postpartum period (Yost et al, 1999). In contrast,
high prevalence rates of high-risk HPV have been found in preg-
nant women (Rando et al, 1989; Saito et al, 1995; Morrison et
al, 1996; Fife et al, 1999), although in other studies no differences
in HPV prevalence between pregnant and non-pregnant women
were seen (Peng et al, 1990; Kemp et al, 1992; De Roda Husman
et al, 1995a). In short, the inﬂuence of pregnancy on the natural
course of infection with high-risk HPV types is not yet known.
We performed a non-intervention follow-up study in 353
women referred for colposcopy because of abnormal cervical cytol-
ogy and compared high-risk HPV clearance in pregnant women
with that of non-pregnant women. Our main questions were: (1)
do high-risk HPV rates change during pregnancy?; and (2) is there
any difference between HPV clearance in pregnant and non-preg-
nant women?
MATERIALS AND METHODS
Women
From June 1990 to December 1992, 353 women referred to the
colposcopy clinic of the University Hospital Vrije Universiteit,
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www.bjcancer.comAmsterdam, were followed in a non-intervention study. The char-
acteristics of this cohort have been described previously
(Nobbenhuis et al, 1999, 2001). Brieﬂy, the inclusion criteria were:
referral because of an abnormal cervical smear (i.e. mild to severe
dyskaryosis); age 18–55 years; no history of cervical pathology,
prenatal diethylstilbestrol exposure, or concomitant cancer; no
HIV or immunosuppression, and sufﬁcient Dutch or English
language skills. The median follow-up time was 33 months (range
3–74). Enrolment into the study (baseline) took place about 2
months after referral.
Ninety-one women were pregnant during follow-up. The ﬁrst
recorded full term pregnancy in each woman was used to compu-
ter-high-risk HPV prevalence rates and analyse high-risk HPV
clearance. For the analysis of high-risk HPV clearance we excluded
four pregnancies ending in abortion and four women who acquired
HPV during follow-up prior to their pregnancy. One hundred and
seventy-nine non-pregnant women with a positive high-risk HPV
test at baseline (Figure 1; group A) and 38 pregnant women with
a positive high-risk HPV test at their ﬁrst visit during pregnancy
(Figure 1; groups B and C) were used to study high-risk HPV
clearance between pregnant and non-pregnant women.
Women were monitored every 3 to 4 months by cytology,
colposcopy and HPV testing (Remmink et al, 1995; Nobbenhuis
et al, 1999, 2001). Clinicians and laboratory staff were blinded
for HPV test results and clinical ﬁndings, respectively. No biopsy
samples were taken during follow-up to avoid any interference with
the natural course of the disease. Follow-up ended if women
reached clinical progression (n=33), deﬁned as a colposcopic
impression of CIN 3 covering three or more cervical quadrants
or a cervical smear suspect for microinvasive carcinoma, or at
the end of the study in December 1996. At the last visit, colposco-
pically directed biopsy samples were taken for histological
veriﬁcation of suspected lesions (=end histology). In women with
normal colposcopy, random samples were taken. If necessary,
women were treated according to standard protocols.
The study protocol was approved by the ethics review board of
the hospital, and all women voluntarily signed informed consent
before enrolment.
Human papillomavirus testing
Testing for HPV was done by EIA PCR, which used HPV general-
primer-mediated PCR with the general primers GP 5+/6+ to detect
a broad spectrum of mucosotropic HPV types (De Roda Husman
et al, 1995b; Jacobs et al, 1997). PCR products were used to iden-
tify in one assay all 14 high-risk types using EIA (HPV type 16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). In addition, indi-
vidual high-risk HPV types were determined. This test has been
described previously and has been clinically validated (Jacobs et
al, 1997, 2000).
Deﬁnition of HPV clearance
Women were considered to be clear of infection when no high-risk
HPV type from the previous visit was detected at the next visit
(Nobbenhuis et al, 1999, 2001).
Statistical analysis
We compared pregnant and non-pregnant women in 3 months
periods. In non-pregnant women these periods were designated
from the start of the study. Age distribution at baseline and at time
of pregnancy was compared by the Mann–Whitney test. The Fish-
er-exact test was used to calculate differences in high-risk HPV
rates and abnormal cervical smears in pregnant and non-pregnant
women. We also analysed the prevalence of low-risk HPV types
and multiple HPV infections at different trimesters but the
numbers were too small to draw any conclusions (data not shown).
Not all women were seen in each trimester of pregnancy. There-
fore comparisons for cytology and HPV samples between ﬁrst,
second, and third trimester, or postpartum were made by the
McNemar test, only for those women with specimens available at
both times. Being interested in the effect of pregnancy, only the
ﬁrst postpartum visit within 6 months after delivery was included
in the calculation (range 5–25 weeks after pregnancy). The clear-
ance of high-risk HPV in pregnant and non-pregnant women and
between pregnancy groups (pregnant at the start of the study
versus conceived during the study) were studied by Kaplan–Meier
curves during a period of 12 months. For contrasts we used the
log-rank test. The time-point of HPV clearance was taken at the
mid-point between positive and negative test results for high-risk
HPV (Nobbenhuis et al, 1999, 2001). We included 179 non-preg-
nant women with a high-risk HPV positive test at baseline
(Figure 1; group A) and 38 women with a high-risk HPV positive
test at their ﬁrst visit during pregnancy (Figure 1; groups B and C).
In pregnant women the baseline starting-point for the analysis was
the last menstruation. Cox-regression was performed to calculate
the relative risks (Hazard Rates) to clear high-risk HPV in pregnant
and non-pregnant women in different time periods. Adjustment
was made for women who conceived during follow-up. Through-
out all analyses, a value of P50.05 was considered signiﬁcant.
We did not correct for multiple testing.
RESULTS
The median age in the pregnant and non-pregnant group of
women was 30 years (range 20–44 years) and 32 years (range
19–55 years), respectively (P=0.23). At baseline 68% (179 out of
262) of non-pregnant women had a positive high-risk HPV test
result compared to 63% (57 out of 91) of pregnant women
(P=0.32). At baseline no signiﬁcant difference in number of abnor-
mal cervical smears was observed in high-risk HPV positive
pregnant and non-pregnant women; 133 out of 179 (74%) non-
pregnant women still had an abnormal cervical smear compared
to 15 out of 25 (60%) pregnant women (P=0.13).
Among pregnant women with cervical smears obtained in the
ﬁrst trimester of pregnancy 39% (21 out of 54 available smears)
had abnormal cervical cytology (mild dyskaryosis or worse).
Abnormal cytology in the second, and third trimester and postpar-
tum was present in 42% (25 out of 60), 33% (13 out of 39), and
34% (27 out of 79 available smears), respectively. Comparison of
paired cervical smear samples among the different trimesters with
the postpartum visit did not show any signiﬁcant difference
(P40.1). In non-pregnant women no signiﬁcant difference in
abnormal cervical smears among the different time periods was
found (data not shown).
Prevalence rates of high-risk HPV
In non-pregnant women the prevalence rates of high-risk HPV
obtained from the available samples at the different time periods
(i.e. 3, 6, 9 and 12 months of follow-up) were 64, 57, 53 and
50%, respectively (Table 1).
Among pregnant women whose HPV samples were obtained in
the ﬁrst trimester of pregnancy 50% had positive high-risk HPV
DNA samples (Table 1). The high-risk HPV prevalence rates in
the second and third trimester, and postpartum were 44, 45 and
31%, respectively. Of the remaining 10 women without a postpar-
tum visit, six women wanted to withdraw from the study and had
a cervical biopsy during pregnancy, and four women had a follow-
up visit more than 6 months postpartum. High-risk HPV positive
rates in three monthly periods in the non-pregnant groups were
not signiﬁcantly higher than during pregnancy trimesters and post-
partum (Table 1).
Comparison of paired samples of high-risk HPV among the
three trimester groups in the pregnant women group did not show
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British Journal of Cancer (2002) 87(1), 75–80 ã 2002 Cancer Research UKany statistical difference (data not shown). In 45 women with
paired samples in the ﬁrst trimester and postpartum a signiﬁcant
decline in high-risk HPV positive tests of 51% (23 out of 45) to
33% (15 out of 45) was found (P=0.02). Comparing second trime-
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353 Women referred because of
abnormal cervical cytology
Non-pregnant
n=262
hr-HPV + at baseline
n=179
hr-HPV – at
baseline
n=83
Excluded:
abortion n=4
HPV acquisition
during FU n=4
Pregnant
n=91*
Pregnant at baseline
n=54
Conceived during
F.U. n=29
hr-HPV + at
pregnancy
n=13
hr-HPV + at
pregnancy
n=25
hr-HPV – at
pregnancy
n=29
hr-HPV – at
pregnancy
n=16
* A total of 113 pregnancies were seen during follow-up: 72 women had one, 16 women two, and three
women had three pregnancies. In the clearance analysis only the first full term pregnancy was
included. hr-HPV=high-risk HPV; f.u.=follow-up.
A B C
Figure 1 Characteristics of study groups.
Table 1 Prevalence rates of high-risk HPV in pregnant and non-pregnant women at different
time points during follow-up
Follow-up time No. of samples
No. of high-risk
HPV positive samples
Prevalence of
high-risk HPV (%) P-value
a
Baseline
Non-pregnant 262 179 68 0.32
Pregnant 91 57 63
3 months
Non-pregnant 258 165 64 0.13
Pregnant 52 26 50
6 months
Non-pregnant 244 139 57 0.08
Pregnant 61 27 44
9 months
Non-pregnant 216 114 53 0.38
Pregnant 44 20 45
12 months
Non-pregnant 207 103 50 0.004
Pregnant 81 25 31
aCalculated using Fisher-exact test.
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women) showed a signiﬁcant decline from 45% (24 out of 53) to
32% (17 out of 53) high-risk HPV positive tests (P=0.02). A signif-
icant difference in high-risk HPV rates was also found between the
third trimester and postpartum (paired data available from 40
women) from 48% (19 out of 40) to 25% (10 out of 40) (P=0.004).
High-risk HPV clearance
Twenty-ﬁve high-risk HPV positive women (66%) were pregnant
at baseline (Figure 1; group B) and 13 (34%) became pregnant
during follow-up (Figure 1; group C). We used both groups to
analyse high-risk HPV clearance. To exclude potential bias for
combining these two groups in relation to the starting point we
analysed the inﬂuence of this heterogeneity. Kaplan–Meier curves
did not show differences in clearance rates between the two preg-
nancy groups or with the non-pregnant reference group (log-rank
tests: n.s.). Adjustment for pregnancy groups in Cox regression
analysis did not signiﬁcantly effect the computed relative risks.
Moreover, we did not ﬁnd signiﬁcant differences between the rela-
tive risks in the pregnancy groups. Thus, we did not ﬁnd any
evidence that combining both groups introduces bias.
Among 38 pregnant women with a high-risk HPV positive test
at the ﬁrst visit during pregnancy the cumulative 12-months inci-
dence of high-risk HPV clearance was 42% (95% C.I. 25–59;
ﬁgure not shown). One hundred and seventy-nine non-pregnant
women with a positive high-risk HPV test at baseline had a
cumulative 12-months incidence of high-risk HPV clearance of
31% (95% C.I. 24–38; ﬁgure not shown). Both clearance curves
according to Kaplan–Meier analysis cross at 9 months thus
excluding long term effects on prevalence rates. The crude trime-
ster dependent hazard ratio’s, and the trimester dependent hazard
ratio adjusted for pregnancy groups for HR–HPV clearance
(Table 2), show that the differences between the curves are not
only related with random variation. At 9 to 12 months of
follow-up, i.e. the postpartum period, pregnant women were 4.6
times (95% C.I. 1.6–12.8) more at risk to clear HPV than
non-pregnant women followed during the same time since the
start of the study. The adjusted hazard ratio’s for clearance during
the second and third trimester were 0.35 (95% C.I. 0.05–2.6) and
3.3 (95% C.I. 0.8–13.7), respectively. Trends for decreased high-
risk HPV clearance in cervical smears in pregnant women in
contrast with non-pregnant women are compensated by increased
clearance postpartum. The increased clearance probably already
starts during the third trimester since the crude hazard ratio
was signiﬁcant during that period. Inclusion of more pregnant
women would probably also show a signiﬁcant adjusted hazard
ratio.
DISCUSSION
Our results show that during pregnancy in a group of women initi-
ally referred for colposcopy with an abnormal cervical smear the
prevalence of high-risk HPV is higher than in the postpartum peri-
od. This effect is also demonstrated by the trimester dependent
HPV clearance rates; during the postpartum period women were
more at risk to clear high-risk HPV than non-pregnant women.
The high-risk HPV prevalence rates in pregnant women varied
between 45 and 50% during the trimesters, and 31% in the post-
partum period. Similar ﬁgures were found by others. Kemp et al
(1992) found HPV prevalence rates of up to 42% and Fife et al
(1999) up to 36% during pregnancy. However, most of these
women had normal cervical cytology smears and were performed
in a pregnant population of young women with a high incidence
of sexual transmitted diseases.
Using a variety of HPV detection techniques, several other
studies also have found a signiﬁcantly higher prevalence of high-
risk HPV during pregnancy in comparison with the postpartum
period (Rando et al, 1989; Saito et al, 1995; Fife et al, 1999; Yost
et al, 1999). Several reasons for this phenomenon have been postu-
lated. It has been suggested that pregnant women tend to have
fewer sexual partners than non-pregnant women of the same age
(De Roda Husman et al, 1995a) and therefore have a decreased risk
to acquire a new HPV infection (Peng et al, 1990; Tenti et al,
1997). Pregnancy-related explanations for this change in HPV
prevalence have been given in terms of possible selective activation
of viruses by hormonal (von Knebel Doeberitz et al, 1991; Michelin
et al, 1997) and immunological factors (Sethi et al, 1998). Sethi et
al (1998) showed that serologic response to HPV type 16 was high-
er in non-pregnant than in pregnant women suggesting that
pregnancy reduces humoral immune response against HPV. In
pregnant women we found reduced high-risk HPV clearance
during pregnancy with a catch-up postpartum, suggesting that an
altered immune-response may be present during pregnancy. Unfor-
tunately, we could not test this since in only a few women blood
serum was taken during follow-up. Our study shows that postpar-
tum pregnant women clear HR–HPV faster than non-pregnant
women after a same period of follow-up. This downward trend
in high-risk HPV prevalence postpartum may be explained by
cervical trauma occurring at the time of delivery with additional
repair of the cervical epithelium (Yost et al, 1999). Indeed, in a
study in which postpartum regression rates of cervical lesions were
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Table 2 Relative risks to clear high-risk HPV in pregnant and non-pregnant women at different
time periods
Time period
Women at risk at
start of period
Crude hazard ratio
(95% C.I.)
Adjusted hazard ratio
a
(95% C.I.)
0–3 months
Non-pregnant 179 1.0 1.0
Pregnant 38 NA
b NA
b
3–6 months
Non-pregnant 156 1.0 1.0
Pregnant 37 0.7 (0.2–2.3) 0.35 (0.05–2.6)
6–9 months
Non-pregnant 128 1.0 1.0
Pregnant 34 3.7 (1.1–12.8) 3.3 (0.8–13.7)
9–12 months
Non-pregnant 105 1.0 1.0
Pregnant 27 3.4 (1.3–9.1) 4.6 (1.6–12.8)
aAdjusted for women who conceived during follow-up.
bHazard ratio was not applicable since none of the
women reached the endpoint.
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section, a higher postpartum regression was seen in women with
vaginal deliveries probably due to stimulation of local immune
factors (Ahdoot et al, 1998).
From recent studies we know that HPV clearance is associated
with and precedes on average 3 months regression of cervical
lesions (Nobbenhuis et al, 2001; Zielinski et al, 2001). Thus, follow-
ing clearance an increased regression rate of cervical lesions could
be expected postpartum. This phenomenon was already described
by Yost et al (1999). However, during a 12-month period they
found no difference in clearance rates between pregnant and
non-pregnant women. These results indicate that pregnant women
with a high-risk HPV positive test during pregnancy are not at
higher risk for progression of underlying lesions than non-pregnant
women. Indeed, when we followed our women for an additional 6
months period the cumulative incidence of HPV clearance in preg-
nant and non-pregnant women became similar (data not shown).
In addition, no difference in number of women with progressive
CIN was seen in the follow-up of pregnant and non-pregnant
women with high-risk HPV positive tests, suggesting that both
groups are at similar risks over a period of 1½ years (data not
shown).
In conclusion, although at long term the course of a high-risk
HPV infection is not affected we found evidence that pregnancy
inﬂuences high-risk HPV clearance. Trends for a decreased high-
risk HPV clearance in the ﬁrst two trimesters in pregnant women
in contrast with non-pregnant women are compensated by
increased clearance demonstrable postpartum but already starting
in the third trimester.
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